An inhibitor of Bcl-2 family proteins induces regression of solid tumours

Tilman Oltersdorf, Steven W. Elmore, Alexander R. Shoemaker, Robert C. Armstrong, David J. Augeri, Barbara A. Belli, Milan Bruncko, Thomas L. Deckwerth, Jurgen Dinges, Philip J. Hajduk, Mary K. Joseph, Shinichi Kitada, Stanley J. Korsmeyer, Aaron R. Kunzer, Anthony Letai, Chi Li, Michael J. Mitten, David G. Nettesheim, Shi Chung Ng, Paul M. NimmerJacqueline M. O'Connor, Anatol Oleksijew, Andrew M. Petros, John C. Reed, Wang Shen, Stephen K. Tahir, Craig B. Thompson, Kevin J. Tomaselli, Baole Wang, Michael D. Wendt, Haichao Zhang, Stephen W. Fesik, Saul H. Rosenberg

Research output: Contribution to journalArticlepeer-review

2804 Scopus citations


Proteins in the Bcl-2 family are central regulators of programmed cell death, and members that inhibit apoptosis, such as Bcl-XL and Bcl-2, are overexpressed in many cancers and contribute to tumour initiation, progression and resistance to therapy. Bcl-XL expression correlates with chemo-resistance of tumour cell lines, and reductions in Bcl-2 increase sensitivity to anticancer drugs and enhance in vivo survival. The development of inhibitors of these proteins as potential anti-cancer therapeutics has been previously explored, but obtaining potent small-molecule inhibitors has proved difficult owing to the necessity of targeting a protein-protein interaction. Here, using nuclear magnetic resonance (NMR)-based screening, parallel synthesis and structure-based design, we have discovered ABT-737, a small-molecule inhibitor of the anti-apoptotic proteins Bcl-2, Bcl-XL and Bcl-w, with an affinity two to three orders of magnitude more potent than previously reported compounds. Mechanistic studies reveal that ABT-737 does not directly initiate the apoptotic process, but enhances the effects of death signals, displaying synergistic cytotoxicity with chemotherapeutics and radiation. ABT-737 exhibits single-agent-mechanism-based killing of cells from lymphoma and small-cell lung carcinoma lines, as well as primary patient-derived cells, and in animal models, ABT-737 improves survival, causes regression of established tumours, and produces cures in a high percentage of the mice.

Original languageEnglish (US)
Pages (from-to)677-681
Number of pages5
Issue number7042
StatePublished - Jun 2 2005
Externally publishedYes

All Science Journal Classification (ASJC) codes

  • General


Dive into the research topics of 'An inhibitor of Bcl-2 family proteins induces regression of solid tumours'. Together they form a unique fingerprint.

Cite this